Elsevier

Current Opinion in Pharmacology

Volume 14, February 2014, Pages 97-102
Current Opinion in Pharmacology

Schizophrenia: from dopaminergic to glutamatergic interventions

https://doi.org/10.1016/j.coph.2014.01.001Get rights and content

Highlights

Schizophrenia might be considered a neurodevelopmental disease. However, the fundamental process(es) associated with this disease remain(s) uncertain. Many lines of evidence suggest that schizophrenia is associated with excessive stimulation of dopamine D2 receptors in the associative striatum, with a lack of stimulation of dopamine D1 receptors in prefrontal cortex, and with modifications in prefrontal neuronal connectivity involving glutamate transmission at N-methyl aspartate (NMDA) receptors. This article, whilst briefly discussing the current knowledge of the disease, mainly concentrates on the NMDA hypofunction hypothesis. However, there are also potential consequences for a Dopamine imbalance on NMDA function. Thus, it is proposed that schizophrenia has a complex aetiology associated with strongly interconnected aberrations of dopamine and glutamate transmission.

Introduction

Schizophrenia is a chronic and severe mental illness with a prevalence of 0.5–1% of the population. Quoting Insel [1] ‘Schizophrenia is a syndrome: a collection of signs and symptoms of unknown aetiology, predominantly defined by observed signs of psychosis. In its most common form, schizophrenia presents with paranoid delusions and auditory hallucinations late in adolescence or in early adulthood. These manifestations of the disorder have changed little over the past century’. In addition, to these ‘positive’ symptoms schizophrenics also exhibit ‘negative’ and ‘cognitive’ symptoms [1]. Negative symptoms include: flattening, speech poverty, apathy, lack of pleasure and withdrawal, whilst cognitive deficits include attention, executive functioning, memory and speed of processing. Some of the symptoms of schizophrenia have been modeled in man using specific pharmacological agents [2, 3]. The rationale for the choice of these agents has relied on current hypotheses of the aetiology of schizophrenia, as described below. However, data have suggested that schizophrenia is a neurodevelopmental disorder that involves alterations in brain circuits. Psychotic symptoms nearly always emerge during adolescence or early adulthood (i.e. between 18 and 25 years of age). However, this does not mean that earlier in life schizophrenics perform well [4, 5, 6]. These longitudinal population studies suggest delayed maturation, especially in the first year of life and that IQ is reduced early and persistently in children that will develop schizophrenia. If indeed schizophrenia is a developmental disease, it may not be possible to develop truly relevant models of schizophrenia in either animals or man. However, Thompson and Levitt [7] have suggested that a lesion early in development may not manifest itself until later in development when compensatory mechanisms may not apply (developmental allostasis). Puberty or its consequences seem to be the defining moment. If true, then circuit and neurotransmitter dysfunctions seen in full blown schizophrenia may be the consequences of the initial lesion.

While this aetiology of schizophrenia remains unclear, there is substantial evidence that suggests that there are changes in several neurotransmitter systems in the pathophysiological processes leading to the formation of schizophrenia. Initially, dopamine (DA) and two of its specific receptors in different brain areas received most attention. Subsequently, glutamate (GLU) and one of its receptors (N-methyl aspartate NMDA) have entered the scene [8, 9]. Other systems have also been suspected. These include the GABAergic, opioid, cholinergic or serotonergic systems.

It has been proposed that positive symptoms observed in schizophrenics are due to a hyperactivity of DA transmission [10]. Evidence for the DA hypothesis has come mainly from two sources: the finding of a correlation between clinical doses of antipsychotic drugs and their efficacy to block DA D2 receptors [8, 10] and the fact that DA enhancing molecules are psychotogenic (for review see [2, 9]). The classical DA hypothesis has become associated with subcortical regions of the brain such as the striatum and the nucleus accumbens, based on the high concentration of DA terminals and D2 receptors in these structures.

Resistance to D2 antagonists by negative and cognitive symptoms of schizophrenia has led to reformiting the DA hypothesis. The use of functional brain imaging has suggested that the prefrontal cortex (PFC) might be responsible for these symptoms (for reviews see [3]). Preclinical studies have shown the importance of prefrontal DA transmission at D1 receptors (the principle DA receptor in the neocortex) (for review see [11]). This has created a hypothesis that a deficit in DA transmission at D1 receptors in the PFC might be involved in the cognitive impairments and negative symptoms of schizophrenia [12, 13].

Much evidence supports the idea that schizophrenia might also be associated with a persistent defect in GLU transmission involving NMDA receptors (for reviews see [14, 15, 16, 17, 18]). Convergence of both preclinical and clinical data [14, 19, 20] suggest that dysfunction of DA systems in schizophrenia may be following to a deficit in NMDA receptor function. In addition, it is now understood that DA has a modulatory role on GLU performance. Thus, changes in DA function might in turn affect NMDA activity.

In this paper, we briefly review recent imaging evidence on the role in schizophrenia of DA dysfunction and that suggesting this dysfunction is secondary to NMDA dysfunction.

Section snippets

Striatal DA function in schizophrenia

Molecular imaging studies have proved to be a powerful tool in increasing our understanding of the structures and mechanisms involved in schizophrenia.

Several methodologies have been used to show that during psychotic episodes there is an increased D2 receptor activation [21, 22, 23, 24, 25, 26, 27, 28]. For example, increased rates of [18F]DOPA accumulation have been observed in schizophrenics indicating higher DA synthesis. A higher [18F]DOPA uptake was also seen in subjects with ‘prodromal’

A neuronal circuitry model of GLU–DA interactions

A model described by Carlsson et al. [29, 52] hypothesises that GLU can affect DA activity in the substantia nigra (SN) and ventral tegmental area (VTA). A deficiency of NMDA transmission leading to diminished prefrontal activity in schizophrenics might cause a lowering of mesocortical DA transmission making worse cognitive function. If maintained, this lesion of mesolimbic DA transmission is hypothesised to trigger positive symptoms.

Imaging studies of GLU–DA interactions

When NMDA antagonists are administered acutely there has been

DA–GLU interaction in the striatum

Stimulation of either D1 or D2 receptors in the striatum has divergent activity on NMDA transmission. From an anatomical point of view, GLU afferents from the cortex and DA projections coincide in the striatum on GABAergic medium spiny neurons. Here DA has strong consequences on GLU transmission (for reviews, see [55, 56, 57, 58, 59, 60]). It has been noted that D2 receptor excitement reduces NMDA-mediated GLU, and D1 receptor activation aids GLU transmission [61, 62].

Imaging data (see above)

Conclusions

Schizophrenia can be considered a neurodevelopmental disease that manifests itself in adolescence or young adulthood through a first psychotic episode. However, there are other domains of schizophrenia, such as cognitive impairment, that might be present prodromal.

Imaging data support the concept that there is an association between schizophrenia and an endophenotype consisting of a DA function deficit in the cortex together with an excess of DA activity in the AST. Imaging and animal data

References (74)

  • G. Tsai et al.

    D-serine added to antipsychotics for the treatment of schizophrenia

    Biol Psychiatry

    (1998)
  • C.R. Yang et al.

    Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex

    Neuropsychopharmacology

    (1999)
  • R. Kotter

    Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum

    Prog Neurobiol

    (1994)
  • C. Konradi et al.

    Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment

    Pharmacol Ther

    (2003)
  • A. Del Arco et al.

    Endogenous dopamine potentiates the effects of glutamate on extracellular GABA in the prefrontal cortex of the freely moving rat

    Brain Res Bull

    (2000)
  • T.R. Insel

    Rethinking schizophrenia

    Nature

    (2010)
  • M.B. Knable et al.

    Dopamine, the prefrontal cortex and schizophrenia

    J Psychopharmacol

    (1997)
  • K.A. Woodberry et al.

    Premorbid IQ in schizophrenia: a meta-analytic review

    Am J Psychiatry

    (2008)
  • A. Reichenberg et al.

    Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study

    Am J Psychiatry

    (2010)
  • I. Creese et al.

    Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

    Science

    (1976)
  • J.A. Lieberman et al.

    Provocative tests with psychostimulant drugs in schizophrenia

    Psychopharmacology

    (1987)
  • P. Seeman et al.

    Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons

    Science

    (1975)
  • K.L. Davis et al.

    Dopamine in schizophrenia: a review and reconceptualization

    Am J Psychiatry

    (1991)
  • D.R. Weinberger

    Implications of the normal brain development for the pathogenesis of schizophrenia

    Arch Gen Psychiatry

    (1987)
  • J.W. Olney et al.

    Glutamate receptor dysfunction and schizophrenia

    Arch Gen Psychiatry

    (1995)
  • D.C. Javitt et al.

    Recent advances in the phencyclidine model of schizophrenia

    Am J Psychiatry

    (1991)
  • C.A. Tamminga et al.

    Glutamate pharmacology and the treatment of schizophrenia: current status and future directions

    Int Clin Psychopharmacology

    (1995)
  • D.C. Goff et al.

    The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

    Am J Psychiatry

    (2001)
  • M. Laruelle et al.

    Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates

    Synapse

    (1997)
  • A. Breier et al.

    Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method

    Proc Natl Acad Sci U S A

    (1997)
  • L.S. Kegeles et al.

    Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans

    Synapse

    (1999)
  • P. Piccini et al.

    Endogenous dopamine release after pharmacological challenges in Parkinson's disease

    Ann Neurol

    (2003)
  • V.L. Villemagne et al.

    GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans

    Synapse

    (1999)
  • M. Laruelle et al.

    Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects

    Proc Natl Acad Sci U S A

    (1996)
  • A. Abi-Dargham et al.

    Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort

    Am J Psychiatry

    (1998)
  • O.D. Howes et al.

    Elevated striatal dopamine function linked to prodromal signs of schizophrenia

    Arch Gen Psychiatry

    (2009)
  • R. Narendran et al.

    Positron emission tomography imaging of dopamine D2 receptors in the human cortex with [(1)(1)C]FLB 457: reproducibility studies

    Synapse

    (2010)
  • Cited by (125)

    View all citing articles on Scopus
    View full text